Polymyositis News

The FDA has granted rare pediatric disease designation to Descartes-08, an autologous mRNA cell therapy, for the treatment of juvenile dermatomyositis, Cartesian Therapeutics announced in a press release.

Nearly 1 year ago, I wrote my first editorial about the emergence and excitement surrounding the early experience with CAR T cells — CAR T Cells in Autoimmunity: A Potential Therapy About to Explode.

ORLANDO, Fla. — Malignancies and lung involvement are the two key manifestations of dermatomyositis that require vigilance, according to a presenter at the 2024 Rheumatology Nurses Society annual conference.

Rheumatoid arthritis and fibromyalgia are among the most common comorbidities identified in patients following a diagnosis of osteoarthritis, according to data presented at the EULAR 2024 Congress.

DESTIN, Fla. — Positive results for chimeric antigen receptor T-cell therapy in systemic sclerosis and myositis have added fuel to the fire of recent landmark data in lupus, said a speaker at the Congress of Clinical Rheumatology East.

DESTIN, Fla. — Although the strongest predictor of malignancy in dermatomyositis is age, all adult patients should undergo cancer screening, according to a speaker at the Congress of Clinical Rheumatology East annual meeting.

Single injections of CD19 chimeric antigen receptor T-cell therapy brought long-lasting remission to 15 patients with three different autoimmune diseases, according to data published in The New England Journal of Medicine.

Chimeric antigen receptor T-cell therapy produced persistent, drug-free remission in patients with one of three different B-cell autoimmune diseases, researchers reported at ASH Annual Meeting and Exhibition.

SAN DIEGO — Pregnant patients with concomitant systemic lupus erythematosus and antiphospholipid syndrome have an 18-fold increased risk for cardiovascular events vs. healthy pregnant controls, said a speaker at ACR Convergence 2023.